hrp0089p1-p035 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Long-term Outcomes of Osteogenesis Imperfecta in the Bisphosphonate Era

Feehan Andrew , Zacharin Margaret , Lim Angelina , Simm Peter

Background: Bisphosphonates have been used for treatment of bone fragility disorders for over 25 years to increase bone mineral density (BMD). Anecdotally, bisphosphonate-treated Osteogenesis Imperfecta (OI) has a different trajectory to the natural history of untreated OI, with minimal published evidence to support this clinical observation.Aims: To describe functional outcomes of a cohort of adults with OI, stratified according to severity and treated ...

hrp0089p3-p075 | Diabetes & Insulin P3 | ESPE2018

First Four Cases of Neonatal Diabetes from Kazakhstan, Almaty with Proven Mutations in KCNJ11 and INS Genes

Nurbekova Akmaral , Hattersley Andrew , Ten Svetlana , Bhangoo Amrit

We report three cases of neonatal diabetes from Kazakhstan, Almaty with the KCNJ11 gene mutation who were successfully switched from insulin to sulphonylurea treatment and 1 case of insulin (INS) gene mutation that presented as permanent insulin dependent neonatal diabetes.Case 1: An 1 month old girl presented with elevated glucose level, dehydation, ketoacidosis and was treated with Insulin. HbA1c at diagnosis was 10%. Heterozygous missense mut...

hrp0089p3-p076 | Diabetes & Insulin P3 | ESPE2018

First 2 Cases of Monogenic Diabetes (MODY) from Kazakhstan, Almaty with Proven Heterozygous Mutation in Hepatocyte Nuclear Factor 1-Alpha (HNF1A) Gene

Nurbekova Akmaral , Hattersley Andrew , Ten Svetlana , Bhangoo Amrit

Background: It is important to make correct diagnosis of monogenic diabetes or MODY in children. Most of the patients are misdiagnosed with diabetes type 1 or type 2 and undergo unnecessary treatment with insulin or oral medications. We report first 1 case of MODY with heterozygous mutation in HNF1A gene when Insulin treatment was changed to sulphonylurea treatment and 1 case of compound heterozygote of glucokinase (GCK) gene and HNF1A gene mutations.Cas...

hrp0086fc14.6 | Growth : Mechanisms | ESPE2016

In vitro and in vivo Evidence for a Growth Inhibitory Role of the Transcription Factor ZBTB38 Throughout Pre- and Post-Natal Life

Parsons Sam , Stevens Adam , Whatmore Andrew , Murray Philip , Clayton Peter

Background: Single nucleotide polymorphisms (SNPs) within the promotor and 5Â’UTR of the transcriptional factor, ZBTB38, are associated with adult height and idiopathic short stature although their precise auxological effects have not previously been described. In addition, the molecular mechanisms through which ZBTB38 affects growth have not been fully elucidated but potential downstream mediators are suggested to include MCM10 or IGF2.Objectives: <...

hrp0082p3-d1-908 | Pituitary | ESPE2014

Macroprolactinoma in Adolescence: a Case Report

Scott Amanda , Velayutham Valli , Campbell Robert , Cuneo Ross , Cotterill Andrew

Background: Prolactinomas are relatively rare during childhood, with an incidence of 0.1 per million. Children with hyperprolactinaemia have widely varied presentations depending on age, sex, and tumour size. Whilst adults typically present with galactorrhoea or hypogonadism, children tend to present with pubertal delay and growth issues.Objective and hypotheses: Poorer surgical outcomes have been reported in children with macroprolactinomas compared to ...

hrp0084p2-305 | DSD | ESPE2015

‘www.steroidogenicfactor-1.info’: An Online Database of Variants in Steroidogenic Factor 1 (SF-1, NR5A1) and Resource for Families and Professional Healthcare Providers

Suntharalingham Jenifer , Buonocore Federica , Duncan Andrew , Achermann John

Background: Steroidogenic factor 1 (SF1), encoded by the gene NR5A1, is a member of the orphan nuclear receptor superfamily and important regulator of gonadal and adrenal function. Variations in SF1 lead to a spectrum of conditions including 46,XY DSD, hypospadias, adrenal insufficiency, male factor infertility, and primary ovarian insufficiency. Inheritance patterns can be complicated (e.g. de novo dominant, sex-limited dominant, and autosomal recessive). In...

hrp0084p3-1065 | Hypo | ESPE2015

Glycogen-Storage Disease Type VI in a Girl Presenting with Recurrent Ketotic Hypoglycaemia but No Hepatomegaly

Price Victoria , Didi Mohammed , Morris Andrew , Senniappan Senthil

Background: Glycogen-storage disease type VI (GSD VI) is an autosomal recessive disorder due to deficiency of the liver isoform of phosphorylase resulting in abnormal accumulation of glycogen. Patients typically present in early childhood with growth retardation, hepatomegaly, hypoglycaemia and ketosis. Ketotic hypoglycaemia is a relatively common diagnosis (of exclusion) in children presenting with hypoglycaemia.Case: A 3-year-old girl presented with an...

hrp0094p1-76 | Fetal Endocrinology and Multisystem Disorders A | ESPE2021

Hyperinsulinemic Hypoglycemia in a child with Peroxisomal Biogenesis Disorder due to a Novel PEX1 mutation

Lohiya Nikhil , Morris Andrew , Didi Mohamed , Senniappan Senthil ,

Introduction: Peroxisomal biogenesis disorders - Zellweger Syndrome Spectrum (PBD-ZWS) are rare disorders involving multiple systems including the central nervous system, adrenals, liver and skeleton but hyperinsulinism is not a recognized association. We present a child with PBD-ZWS due to a novel mutation in PEX1 who developed hyperinsulinaemic hypoglycaemia (HH).Case report: A 7 month old boy presented with recurrent hypoglyc...

hrp0094p2-22 | Adrenals and HPA Axis | ESPE2021

Prevalence of adrenal insufficiency (AI) requiring treatment with hydrocortisone in children tested with the LDSST

Park Julie , Selvarajah Bhavana , Titman Andrew , Blair Joanne ,

Synacthen tests are used widely in paediatric practice for diagnosis of AI. The standard dose test may be more specific and low dose test (LDSST), more sensitive. The LDSST requires dilution of commercially available Synacthen, which may result in unreliable dosing and over diagnosis of AI.Aim: To determine the prevalence of AI requiring treatment with hydrocortisone (a) daily (peak cortisol <350nmol/l) (b) on sick days only (peak co...

hrp0097fc10.2 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) &amp; Multisystem endocrine disorders | ESPE2023

Immune profile response to rituximab in ROHHAD syndrome

Hawton Katherine , Hamilton-Shield Julian , Hogan Andrew , Giri Dinesh

Background: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD) is a rare syndrome associated with high morbidity and mortality presenting with rapid onset of obesity in early childhood. An immune-inflammatory aetiology has been postulated; however, the immune profile is not well described.Case report: We report the case of a five-year-old female who presented in respirato...